{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:26:46Z","timestamp":1777858006886,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T00:00:00Z","timestamp":1229040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>This 12-week, double-blind, two-part study in 438 adults with bipolar-associated acute mania began with a 3-week period comparing ziprasidone (80\u2014160 mg\/day) and placebo with haloperidol (8\u201430 mg\/day) as active reference. Changes from baseline Mania Rating Scale (MRS) scores for ziprasidone and haloperidol were superior to placebo from day 2 (P = 0.001) to week 3 (P &lt; 0.001); change from baseline at week 3 was greater for haloperidol than ziprasidone (P \u2264 0.001). At week 3, the response rate (\u226550% decrease from baseline MRS score) was 36.9, 54.7 and 20.5% for ziprasidone, haloperidol and placebo, respectively (P \u2264 0.05, active treatments versus placebo and ziprasidone versus haloperidol). In the 9-week extension phase, ziprasidone replaced placebo to examine tolerability. Maintenance of improvement was evaluated for ziprasidone (40\u2014160 mg\/day) or haloperidol (4\u201430 mg\/day). Responses were maintained through the last visit for 88.1% receiving ziprasidone and 96.3% receiving haloperidol. More patients receiving haloperidol than ziprasidone discontinued treatment during weeks 4\u201412 (21.1% versus 9.6%) and had significantly higher rates of movement disorders. Mean doses of ziprasidone and haloperidol for the first 3-week and 9-week extension were 116.2 mg\/day and 121.4 mg\/day and 16.0 mg\/day and 16.1 mg\/day, respectively. Ziprasidone was shown to be effective monotherapy for acute treatment of bipolar mania. Although haloperidol showed greater efficacy, ziprasidone showed a superior tolerability profile.<\/jats:p>","DOI":"10.1177\/0269881108099418","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T21:36:32Z","timestamp":1229117792000},"page":"547-558","source":"Crossref","is-referenced-by-count":63,"title":["Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study"],"prefix":"10.1177","volume":"24","author":[{"given":"E.","family":"Vieta","sequence":"first","affiliation":[{"name":"Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ramey","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Keller","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PA","family":"English","sequence":"additional","affiliation":[{"name":"La Jolla Laboratories, Pfizer Inc, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AD","family":"Loebel","sequence":"additional","affiliation":[{"name":"Dainippon Sumitomo Pharma America, Inc, Fort Lee, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Miceli","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,12,12]]},"reference":[{"key":"atypb1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"Allison, DB","year":"1999","journal-title":"Am J Psychiatry"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0219"},{"issue":"4","key":"atypb3","first-page":"1","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am J Psychiatry"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01643-8"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1002\/hup.657"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.06.014"},{"issue":"18","key":"atypb7","first-page":"27","volume":"65","author":"Casey, DE","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07253-4"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199808000-00009"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.3109\/15622970309167904"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0609"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050755"},{"key":"atypb14","volume-title":"Presented at: American Psychiatric Association","author":"Keck Jr, PE"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01672-4"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.229"},{"key":"atypb19","first-page":"142","volume":"57","author":"McElroy, SL","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.02.006"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000169068.34322.70"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.04.022"},{"key":"atypb23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","volume":"275","author":"Seeger, TF","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb24","first-page":"176","volume":"21","author":"Segal, J.","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.8.1535"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.06.003"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.12.1218"},{"key":"atypb28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","volume":"156","author":"Tohen, M.","year":"1999","journal-title":"Am J Psychiatry"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-200301000-00006"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.235"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X46340"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0607"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108099418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108099418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:48Z","timestamp":1777507548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108099418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1177\/0269881108099418"],"URL":"https:\/\/doi.org\/10.1177\/0269881108099418","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,12]]}}}